Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treat...
Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study
About this item
Full title
Author / Creator
Publisher
New Zealand: Dove Medical Press Limited
Journal title
Language
English
Formats
Publication information
Publisher
New Zealand: Dove Medical Press Limited
Subjects
More information
Scope and Contents
Contents
This study aimed to compare the efficacy and safety of generic and branded irbesartan for 8 weeks in patients with mild-to-moderate essential hypertension.
We screened 221 patients with mild-to-moderate hypertension. After exclusion per study criteria, 177 subjects were randomized to receive 150 mg generic irbesartan (n=91) or branded irbesartan...
Alternative Titles
Full title
Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_3de1a120ad9242d89b5c8c6488ee3b45
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_3de1a120ad9242d89b5c8c6488ee3b45
Other Identifiers
ISSN
1177-8881
E-ISSN
1177-8881
DOI
10.2147/DDDT.S172046
